Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma

13 May 2013

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Renal and related cancers
Share to Sarcoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23665679
DOI: 10.1038/onc.2013.129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcomaPMID 23665679Read ↗

Update on molecular findings in rhabdomyosarcomaSemantic proximity Read ↗

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity.Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

Market watch: emerging companion diagnostics for cancer drugs.Semantic proximity Read ↗

Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionSemantic proximity Read ↗

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaSemantic proximity Read ↗

Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathwaySemantic proximity Read ↗

RET-oncogene-targeting drugs draw notice.Semantic proximity Read ↗

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypesSemantic proximity Read ↗

Zebrafish avatars: towards functional precision medicine in low-grade serous ovarian cancerSemantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

Advances in drug development. BRAF validation in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.